Invention Grant
- Patent Title: Antibodies directed against programmed death-1 (PD-1)
-
Application No.: US15726287Application Date: 2017-10-05
-
Publication No.: US10738117B2Publication Date: 2020-08-11
- Inventor: David J. King , Marilyn Kehry
- Applicant: AnaptysBio, Inc.
- Applicant Address: US CA San Diego
- Assignee: ANAPTYSBIO, INC.
- Current Assignee: ANAPTYSBIO, INC.
- Current Assignee Address: US CA San Diego
- Agency: Fish & Richardson P.C.
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K39/00
Abstract:
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.
Public/Granted literature
- US20180051082A1 ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 (PD-1) Public/Granted day:2018-02-22
Information query
